Plenaxis

Active Ingredient(s): Abarelix
FDA Approved: * November 25, 2003
Pharm Company: * PRAECIS
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Plenaxis Overview

Abarelix, sold under the brand name Plenaxis, is an injectable gonadotropin-releasing hormone antagonist (GnRH antagonist) which is marketed in Germany and the Netherlands. It is primarily used in oncology to reduce the amount of testosterone made in patients with advanced symptomatic prostate cancer for which no other treatment options are available.[2][3] It was originally marketed by Praecis Pharmaceuticals as Plenaxis,[2] and is now marketed...

Read more Plenaxis Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Abarelix

Recent Plenaxis Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Abarelix
  • Injection: 100mg/vial, 50mg/ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Abarelix or a similar ingredient: (1 result)




Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 18 January 2019.

We are committed to your privacy.

Copyright © 2005-2019 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA